{"prompt": "['9.', 'STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION', '89', '9.1', 'Study Documentation', '89', '9.2', 'Protocol Deviations', '89', '9.3', 'Site Inspections', '89', '9.4', 'Administrative Structure', '89', '9.5', 'Dissemination of Data and Protection of Trade Secrets', '90', '9.6', 'Protocol Amendments', '90', '10. REFERENCES', '92', 'LIST OF TABLES', 'Table 1', 'Reporting Conventions for Left Ventricular Systolic', 'Dysfunction / Congestive Heart Failure', '68', 'Table 2', 'Reporting Conventions for Administration-Related Reactions', '69', 'Table 3', 'Adverse Event Severity Grading Scale for Events Not Specifically', 'Listed in NCI CTCAE', '70', 'Table 4', 'Causal Attribution Guidance', '71', 'LIST OF FIGURES', 'Figure 1', 'Study Schema', '37', 'Figure 2', 'Study Treatment Cycle Calculation', '38', 'LIST OF APPENDICES', 'Appendix 1', 'Schedule of Activities', '95', 'Appendix 2', 'Patient Reported Outcome Measures', '102', 'Appendix 3', 'Healthcare Professional Reported Outcome Measures', '110', 'Appendix 4', 'American Cancer Society / American Society of Clinical Oncology', 'Breast Cancer Survivorship Care Guideline', '123', 'Appendix 5', 'Eastern Cooperative Oncology Group Performance Status Scale', '124', 'Appendix 6', 'Asymptomatic Decline in LVEF: Algorithm for Continuation and', 'Discontinuation of Study Treatment', '125', 'Appendix 7', 'NYHA Functional Classification System for Heart Failure and LVSD', 'NCI CTCAE V4.0 Grading', '126', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '14 / Protocol MO40628, Version 2']['PROTOCOL AMENDMENT ACCEPTANCE FORM', 'TITLE:', 'A RANDOMIZED, MULTICENTER, OPEN-LABEL', 'CROSS-OVER STUDY TO EVALUATE PATIENT', 'PREFERENCE AND SATISFACTION', 'OF', 'SUBCUTANEOUS ADMINISTRATION OF THE', 'FIXED-DOSE COMBINATION OF PERTUZUMAB', 'AND TRASTUZUMAB IN PATIENTS WITH HER2-', 'POSITIVE EARLY BREAST CANCER', 'PROTOCOL NUMBER: MO40628', 'VERSION NUMBER:', '2', 'EUDRACT NUMBER:', '2018-002153-30', 'IND NUMBER:', '131009', 'TEST PRODUCT:', 'Fixed-dose combination of pertuzumab and trastuzumab', 'for subcutaneous administration (RO7198574)', 'MEDICAL MONITOR:', 'Dr.', 'SPONSOR:', 'F. Hoffmann-La Roche Ltd', 'I', 'agree to conduct the study in accordance with the current protocol.', \"Principal Investigator's Name (print)\", \"Principal Investigator's Signature\", 'Date', 'Please retain the signed original of this form for your study files. Please return a copy of the', 'signed form as instructed by your local study monitor.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '15 / Protocol MO40628, Version 2']['PROTOCOL SYNOPSIS', 'TITLE:', 'A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-', 'OVER STUDY TO EVALUATE PATIENT PREFERENCE AND', 'SATISFACTION OF SUBCUTANEOUS ADMINISTRATION', 'OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB', 'AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE', 'EARLY BREAST CANCER', 'PROTOCOL', 'MO40628', 'NUMBER:', 'VERSION NUMBER:', '12', 'EUDRACT NUMBER: 2018-002153-30', 'IND NUMBER:', '131009', 'TEST PRODUCT:', 'Fixed-dose combination of pertuzumab and trastuzumab for', 'subcutaneous administration (RO7198574)', 'PHASE:', 'II', 'INDICATION:', 'HER2-positive Early Breast Cancer', 'SPONSOR:', 'F. Hoffmann-La Roche Ltd', 'Objectives and Endpoints', 'This study will evaluate patient reported preference for a subcutaneously administered fixed-dose', 'combination formulation (FDC SC) of pertuzumab and trastuzumab compared with intravenously (IV)', 'administered PerjetaR and Herceptin\u00ae formulations (P+H IV) in patients with HER2-positive (HER2+)', 'early breast cancer (EBC). The study will also evaluate patient reported satisfaction with pertuzumab', 'and trastuzumab FDC SC and health-related quality of life (HRQoL) outcomes; Healthcare', 'professionals (HCPs) perception of time/resource use and convenience of pertuzumab and', 'trastuzumab FDC SC and P+H IV; as well as the safety and efficacy of each study regimen.', 'Specific objectives and corresponding endpoints for the study are outlined in the following table.', 'Table of Objectives and Corresponding Enpoints', 'Primary Objective', 'Corresponding Endpoint', 'To evaluate patient preference for pertuzumab', 'Proportion of patients who preferred', 'and trastuzumab FDC SC', 'pertuzumab and trastuzumab FDC SC with', 'treatment preference assessed via Question 1', 'of the PPQ', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '16 / Protocol MO40628, Version 42']\n\n###\n\n", "completion": "END"}